FDA approves Abilify for treating autistic irritability

11/23/2009 | Bloomberg Businessweek · RTT News

The FDA approved Abilify for treating irritability in autistic children ages 6 to 17 years. Bristol-Myers Squibb said approval was based on data from two Phase III studies that showed Abilify, when compared with a placebo, significantly improved scores on the Irritability subscale of the Aberrant Behavior Checklist.

View Full Article in:

Bloomberg Businessweek · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC